Teva director exercises 14,492 share units

Teva Pharmaceutical Industries director Nisen Perry exercised previously granted restricted share units into ordinary shares.

Accepted by SEC EDGAR 06/08/2026 - 04:04 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Teva Pharmaceutical Industries director Nisen Perry exercised previously granted restricted share units into ordinary shares. On June 5, 2026, 14,492 restricted share units vested and were settled into 14,492 ordinary shares, bringing Perry’s direct holdings to 119,807 ordinary shares.

Insider Trade Summary

14,492 shares exercised/converted

Exercise 2 txns

Insider Nisen Perry

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Share Units	14,492	$0.00	$0.00
Exercise	Ordinary Shares	14,492	$0.00	$0.00

Holdings After Transaction: Restricted Share Units — 0 contracts (Direct); Ordinary Shares — 119,807 shares (Direct)

Footnotes (3)

1. F1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
2. F2. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
3. F3. Restricted share units were granted on June 5, 2025 and vested on June 5, 2026.

Key Figures

RSUs exercised: 14,492 units Shares received: 14,492 ordinary shares Post-transaction holdings: 119,807 ordinary shares +2 more

5 metrics

RSUs exercised 14,492 units Restricted share units converted into ordinary shares on June 5, 2026

Shares received 14,492 ordinary shares Settlement of vested restricted share units

Post-transaction holdings 119,807 ordinary shares Direct ownership after RSU settlement

Grant date June 5, 2025 Date restricted share units were granted

Vesting date June 5, 2026 Date restricted share units vested

Key Terms

Restricted Share Units, American Depositary Shares, Human Resources and Compensation Committee

3 terms

Restricted Share Units financial

"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share"

Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.

American Depositary Shares financial

"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

Human Resources and Compensation Committee financial

"or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."

A board-level committee that oversees a company’s pay and personnel policies, including executive compensation, employee benefits, hiring, leadership development and succession planning. It matters to investors because the committee shapes incentives, labor costs and management continuity—factors that affect performance, risk and shareholder value—like a coach setting rules and pay that influence how a team performs.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Teva (TEVA) director Nisen Perry report?

Nisen Perry reported exercising 14,492 restricted share units into 14,492 ordinary shares. These units were equity compensation that vested and were settled in stock, increasing his direct holdings to 119,807 ordinary shares.

When did the Teva (TEVA) restricted share units for Nisen Perry vest?

The restricted share units for Nisen Perry were granted on June 5, 2025 and vested on June 5, 2026. Upon vesting, 14,492 units were settled into an equal number of ordinary shares as part of his equity compensation.

How many Teva (TEVA) shares does Nisen Perry hold after this Form 4 filing?

After this transaction, Nisen Perry directly holds 119,807 ordinary shares of Teva. This reflects the addition of 14,492 shares obtained when his restricted share units vested and were settled into ordinary shares on June 5, 2026.

What type of security did Nisen Perry exercise in the Teva (TEVA) Form 4?

Nisen Perry exercised derivative securities in the form of restricted share units. Each restricted share unit represented a contingent right to receive one ordinary share or equivalent cash value, and 14,492 units converted into 14,492 ordinary shares at vesting.

Does the Teva (TEVA) Form 4 show any share sales by Nisen Perry?

The Form 4 shows only the exercise of 14,492 restricted share units into ordinary shares with no reported sales. This is a compensation-related equity settlement, not an open-market purchase or sale, and simply increases his directly held share count.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nisen Perry

(Last) (First) (Middle)

C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.

124 DVORA HANEVI'A ST.,

(Street)

TEL AVIV ISRAEL 6944020

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	06/05/2026		M		14,492	A	(2)	119,807	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Share Units	(2)	06/05/2026		M			14,492	(3)	(3)	Ordinary Shares(1)	14,492	$0	0	D

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

2. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

3. Restricted share units were granted on June 5, 2025 and vested on June 5, 2026.

	/s/ Dov Bergwerk as attorney-in-fact for Perry D. Nisen	06/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)